Twin Capital Management Inc. Has $1.33 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Twin Capital Management Inc. grew its position in Boston Scientific Co. (NYSE:BSX) by 8.6% during the 4th quarter, Holdings Channel reports. The firm owned 22,996 shares of the medical equipment provider’s stock after purchasing an additional 1,816 shares during the quarter. Twin Capital Management Inc.’s holdings in Boston Scientific were worth $1,329,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in BSX. International Assets Investment Management LLC acquired a new position in Boston Scientific during the 1st quarter worth about $54,000. Acadian Asset Management LLC acquired a new position in Boston Scientific during the 1st quarter worth about $35,000. Prudential PLC acquired a new position in Boston Scientific during the 1st quarter worth about $1,076,000. Cetera Investment Advisers lifted its position in Boston Scientific by 24.0% during the 1st quarter. Cetera Investment Advisers now owns 28,793 shares of the medical equipment provider’s stock worth $1,275,000 after buying an additional 5,581 shares in the last quarter. Finally, Sequoia Financial Advisors LLC acquired a new position in Boston Scientific during the 1st quarter worth about $230,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

NYSE BSX opened at $67.42 on Friday. The business has a 50 day simple moving average of $67.21 and a 200 day simple moving average of $59.74. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $69.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.82 and a current ratio of 1.32. The stock has a market cap of $98.91 billion, a price-to-earnings ratio of 63.01, a PEG ratio of 2.38 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a return on equity of 15.99% and a net margin of 11.19%. The business had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.59 billion. During the same period in the prior year, the business earned $0.45 EPS. Analysts anticipate that Boston Scientific Co. will post 2.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Citigroup upped their price target on shares of Boston Scientific from $71.00 to $79.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. BTIG Research reissued a “buy” rating and set a $64.00 price objective on shares of Boston Scientific in a report on Friday, December 29th. Oppenheimer boosted their price objective on Boston Scientific from $58.00 to $68.00 and gave the stock a “market perform” rating in a report on Thursday, February 1st. Royal Bank of Canada boosted their price objective on Boston Scientific from $70.00 to $78.00 and gave the stock an “outperform” rating in a report on Monday. Finally, StockNews.com cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 16th. Two research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $68.50.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig sold 7,000 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total value of $455,210.00. Following the sale, the director now owns 41,374 shares of the company’s stock, valued at $2,690,551.22. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $66.89, for a total value of $467,092.87. Following the completion of the transaction, the executive vice president now owns 56,508 shares in the company, valued at approximately $3,779,820.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 7,000 shares of the company’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total value of $455,210.00. Following the sale, the director now owns 41,374 shares in the company, valued at approximately $2,690,551.22. The disclosure for this sale can be found here. Insiders sold 50,979 shares of company stock valued at $3,418,529 in the last ninety days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.